Olaparib monotherapy is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||30/04/2019|
|Rapid review completed||09/05/2019|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of olaparib compared with the current standard of care.|